Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-label Dose Escalation Trial of BI 1701963 in Combination With Irinotecan in KRAS Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
Conditions
Interventions
BI 1701963
Camptosar®
Locations
1
China
Shanghai East Hospital, Tongji University China
Shanghai, China
Start Date
November 23, 2020
Primary Completion Date
January 18, 2022
Completion Date
January 18, 2022
Last Updated
April 20, 2022
NCT07228832
NCT07286695
NCT06944548
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions